Publications
Making the best of the Private Finance Initiative in the NHS
1 December 2002
This briefing is based on the results of a seminar held in London on 30 May 2002. The seminar titled Building long term partnerships, was organised…
Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty
1 December 2002
Improving the health and life expectancy of the populations of the less developed countries of the world requires both better access to medicines and research and…
Cost-Effectiveness Thresholds: Economic and ethical issues
1 November 2002
The papers in this book are based on the proceedings of a workshop jointly organised by the OHE and the King’s Fund and hosted by the…
Influencing Prescribing in a Primary Care Led NHS
11 January 2002
The aim of the project was to evaluate the likely success of medicines management in a primary care led UK National Health Service (NHS). The methods…
Disability Adjusted Life Years (DALYs) for Decision-Making?
9 January 2002
Disability-adjusted life years (DALYs) were introduced in 1993 amid the pages and policy directives of the World Development Report ‘Investing in Health’ (World Bank, 1993). DALYs…
Interpreting and Addressing Inequalities in Health: From Black to Acheson to Blair to . . . ?
5 January 2002
This paper is an updated and expanded version of the 7th OHE annual lecture delivered on 1 June 2000. It takes account of research published up…
The Life Cycle of Pharmaceuticals: A Cross-National Perspective
1 April 2002
This study provides a life cycle perspective on cross-national differences in pharmaceutical prices, volumes and expenditures. Most previous studies have focused solely on cross-national differences in…
Health Economics: An Introduction to Economic Evaluation
3 January 2002
The second edition of this guide to economic evaluation is significantly extended. This mirrors the development of economic evaluation since the first edition was published in…
Consolidation and Competition in the Pharmaceutical Industry
9 January 2001
A number of potentially important structural developments are taking place in the pharmaceutical industry. On the one hand, we are witnessing a large number of mergers…